A Phase 1b/2a Open-Label, Multi-Center Study to Assess the Safety, Efficacy and Pharmacokinetics of Intrapatient Dose-Adjusted Brequinar and Inhibition of Dihydroorotate Dehydrogenase (DHODH) in Adult Subjects with Acute Myelogenous Leukemia (AML)
MD Anderson Study Status
Brequinar, Brequinar + Ribavirin
A Phase 1b/2a multi-center, open-label, non-randomized study to assess the safety, tolerability and efficacy of dose-adjusted brequinar in adult subjects with acute myeloid leukemia (AML). Ribavirin BID may be added to brequinar twice weekly in eligible subjects.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Acute Myeloid Leukemia
For general questions about clinical trials:
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.